Aclaris Therapeutics, a Wayne, Pennsylvania-based clinical-stage biopharmaceutical company developing treatments for immuno-inflammatory diseases, has begun a Phase 2b trial of its investigational oral drug modzatinib (ATI-2138) in lichen planus (LP), the company announced on November 16, 2026. The U.S. Food and Drug Administration (FDA) has granted modzatinib Fast Track Designation for moderate-to-severe LP.
“There are no FDA-approved therapies for people living with this debilitating disease, and we believe that modzatinib has the potential to be the first mechanistically complete oral therapy in this setting,” said Dr. Jesse Hall, Chief Medical Officer of Aclaris.
Inside the ALPHA Trial
The randomized, double-blind, placebo-controlled ALPHA trial will test two doses of modzatinib against placebo in about 100 patients. Participants will have biopsy-confirmed, moderate-to-severe LP that topical treatments haven’t adequately controlled.
The trial includes three groups of patients. The first to enroll will be patients with oral erosive lichen planus (OLP), whose primary endpoint is the change in the Oral Disease Severity Score at Week 16. Patients with cutaneous lichen planus will be measured by the change in a modified Lichen Planus Area and Severity Index score at Week 16. Patients with lichen planopilaris, which causes scarring hair loss, will be measured by the change in the Lichen Planopilaris Activity Index at Week 24.
Aclaris expects topline results from the OLP group in the second half of 2027.
A Disease With No Approved Treatments
LP is a chronic inflammatory disease driven by CD8 T cells, a type of immune cell. It can cause painful sores in the mouth, permanent scarring hair loss, and genital lesions, and oral LP carries a risk of cancer. According to Aclaris, LP affects an estimated 0.1% to 2% of people worldwide, and there are no FDA-approved targeted therapies. Current treatment focuses on suppressing the immune system and controlling symptoms with topical medicines.
How Modzatinib Works
Modzatinib blocks two enzymes, interleukin-2-inducible T cell kinase (ITK) and Janus kinase 3 (JAK3), to target LP at two points in the immune response. Blocking ITK reduces T cell activation and the immune cell attacks that drive the disease. Blocking JAK3 limits signals that help T cells multiply and survive.
Modzatinib has also been studied in a Phase 2a trial in atopic dermatitis.
“Modzatinib has demonstrated activity in multiple non-clinical disease models, including severe alopecia areata, vitiligo, and rheumatoid arthritis, as well as in a Phase 2a trial in atopic dermatitis with rapid and sustained improvements across clinical and patient-reported measures of disease severity, pruritus, and quality of life,” Dr. Hall said.
What’s Next for the Pipeline
Aclaris also shared upcoming milestones for two other programs. It expects to file an Investigational New Drug (IND) application for ATI-9494, an ITK/TXK inhibitor, this quarter, and to start a Phase 1 trial in the first quarter of 2027. The company also plans to begin a Phase 2b trial of its bispecific antibody ATI-052 in eosinophilic esophagitis in the first quarter of 2027, following its recent Phase 1b results.
About Aclaris Therapeutics
Aclaris develops small-molecule and biologic drugs for immuno-inflammatory diseases. Its KINect® platform designs kinase inhibitors, small molecules that block enzymes involved in chronic inflammation, autoimmune disease, and cancer growth. The company is also developing monoclonal and bispecific antibodies, including dual-targeting approaches. Aclaris also operates Confluence Discovery Technologies, a contract research organization that provides drug discovery and early development services to pharma and biotech companies.
Cautionary Note Regarding Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “anticipate,” “believe,” “expect,” “intend,” “may,” “plan,” “potential,” “will,” and similar expressions, and are based on Aclaris’ current beliefs and expectations. These forward-looking statements include expectations regarding its development plans for modzatinib, ATI-052 and ATI-9494, including its plans to evaluate modzatinib in OLP, CLP and LPP and the timing of top line results, the plans for and timing of initiating an EoE trial for ATI-052, and the plans for and timing of filing an IND, initiating a Phase 1 program for ATI-9494, and the potential therapeutic benefits of modzatinib, including the potential for modzatinib to be a mechanistically complete oral therapy for LP and other immuno-inflammatory disorders. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Risks and uncertainties that may cause actual results to differ materially include uncertainties inherent in the conduct of clinical trials, risks associated with interim, top line and preliminary data, Aclaris’ reliance on third parties over which it may not always have full control, Aclaris’ ability to enter into strategic partnerships on commercially reasonable terms, the uncertainty regarding the macroeconomic environment and other risks and uncertainties that are described in the Risk Factors section of Aclaris’ Annual Report on Form 10-K for the year ended December 31, 2025, and other filings Aclaris makes with the U.S. Securities and Exchange Commission from time to time. These documents are available under the “SEC Filings” page of the “Investors” section of Aclaris’ website at www.aclaristx.com. Any forward-looking statements speak only as of the date of this press release and are based on information available to Aclaris as of the date of this release, and Aclaris assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise.
Aclaris Therapeutics Contact:
Will Roberts Senior Vice President Corporate Communications and Investor Relations (484) 329-2125 [email protected]
Source: Aclaris Therapeutics, Inc., Aclaris Therapeutics, Inc. on November 16, 2026. Republished with credit to the original author. Read the original release.